ACE-86225106

· Acerand Therapeutics (Shanghai) Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ACE-86225106, covering 2025-12-29 to 2025-12-29. Get the full timeline:

Most recent: Clinical Trial Update: Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors [Phase 1, Phase 2]